Skip to main content
    R

    Recursion Pharmaceuticals Inc (RXRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.90
    -0.28 (-8.79%)

    Market Cap: $1.99B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Recursion Pharmaceuticals Inc (RXRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Recursion Pharmaceuticals reported revenue of $74.68M for the fiscal year ended Dec 31, 2025, up 26.9% from the year before. That year, net income was -$644.76M with a net margin of -863.4%, operating cash flow was -$371.81M and free cash flow was -$378.28M. The quarter ended Sep 30, 2026 had revenue of $18.55M and net income of -$119.04M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $2.32M, a compound annual rate of 78.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$74.68M+26.9%5.0%-867.9%-863.4%
    Dec 2024$58.84M+32.0%23.1%-814.1%-788.0%
    Dec 2023$44.58M+11.9%4.5%-785.3%-736.0%
    Dec 2022$39.84M+291.5%-21.2%-616.7%-601.0%
    Dec 2021$10.18M+156.9%100.0%-1795.8%-1832.2%
    Dec 2020$3.96M+70.8%100.0%-2135.7%-2196.0%
    Dec 2019$2.32MN/A100.0%-2692.6%-2668.3%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$74.68M$58.84M$44.58M$39.84M$10.18M$3.96M$2.32M
    Cost of revenue$70.95M$45.24M$42.59M$48.27M$0$0$0
    Gross profit$3.73M$13.60M$1.99M-$8.43M$10.18M$3.96M$2.32M
    Research and development$475.27M$314.42M$241.23M$155.70M$135.27M$63.32M$45.81M
    Operating income-$648.13M-$479.00M-$350.06M-$245.73M-$182.78M-$84.61M-$62.44M
    Net income-$644.76M-$463.66M-$328.07M-$239.48M-$186.48M-$87.01M-$61.88M
    EBITDA-$561.19M-$428.29M-$307.73M-$227.72M-$178.07M-$80.67M-$59.95M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$18.55M$7.67M$6.47M$35.54M$5.17M$19.22M$14.74M$4.55M$26.08M$14.42M$13.79M$10.89M
    Gross profit$8.51M-$3.82M-$6.02M$21.26M-$9.51M-$938.00K-$7.08M-$8.25M$14.00M$5.22M$2.63M$1.01M
    Operating income-$123.18M-$134.97M-$128.50M-$108.33M-$172.20M-$176.23M-$191.37M-$183.77M-$98.35M-$100.54M-$96.34M-$98.93M
    Net income-$119.04M-$131.00M-$117.50M-$108.12M-$162.25M-$171.90M-$202.49M-$178.91M-$95.84M-$97.54M-$91.37M-$93.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $18.66M by $724.64M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$1.47B$1.45B$653.70M$701.29M$610.35M$298.58M$101.43M
    Current assets$812.85M$714.27M$438.14M$569.81M$534.72M$266.44M$76.40M
    Cash and equivalents$743.29M$594.35M$391.56M$549.91M$285.12M$262.13M$69.88M
    Total liabilities$343.26M$413.82M$190.26M$215.48M$67.41M$56.56M$225.70M
    Short-term debt$9.09M$8.43M$41.00K$97.00K$90.00K$1.07M$544.00K
    Long-term debt$9.56M$19.02M$1.10M$536.00K$633.00K$11.41M$12.42M
    Shareholder equity$1.13B$1.03B$463.44M$485.81M$542.94M-$206.29M-$124.27M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.22B$1.21B$1.34B$1.47B$1.40B$1.30B$1.31B$1.45B$726.50M$775.86M$557.85M$653.70M
    Total liabilities$315.90M$297.67M$314.75M$343.26M$352.58M$383.21M$371.29M$413.82M$201.94M$191.41M$156.70M$190.26M
    Cash and equivalents$549.85M$545.68M$654.47M$743.29M$659.84M$525.11M$500.45M$594.35M$427.65M$474.34M$296.33M$391.56M
    Shareholder equity$905.81M$915.00M$1.02B$1.13B$1.05B$919.15M$933.95M$1.03B$524.56M$584.45M$401.15M$463.44M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$371.81M-$359.17M-$287.78M-$83.52M-$158.61M-$45.40M-$57.04M
    Capital expenditures$6.47M$13.70M$11.96M$37.06M$39.80M$5.83M$3.91M
    Free cash flow-$378.28M-$372.87M-$299.74M-$120.58M-$198.41M-$51.23M-$60.95M
    Investing cash flow-$16.87M$260.06M-$10.23M$193.25M-$271.74M-$8.74M-$3.91M
    Financing cash flow$521.53M$304.12M$140.13M$154.34M$458.54M$246.13M$120.41M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$77.41M-$105.95M-$81.10M-$46.07M-$117.36M-$76.42M-$131.96M-$115.43M-$59.23M-$82.22M-$102.30M-$74.08M
    Capital expenditures$407.00K$44.00K$258.00K$1.24M$243.00K$3.15M$1.83M$1.30M$4.56M$1.18M$6.65M$2.07M
    Free cash flow-$77.81M-$105.99M-$81.36M-$47.32M-$117.60M-$79.57M-$133.79M-$116.73M-$63.79M-$83.40M-$108.95M-$76.14M
    Last 12 quarters

    Frequently Asked Questions About RXRX

    What is Recursion Pharmaceuticals' annual revenue?

    Recursion Pharmaceuticals reported revenue of $74.68M for the fiscal year ended Dec 31, 2025.

    How fast is Recursion Pharmaceuticals' revenue growing?

    Revenue was up 26.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 23.3%.

    Is Recursion Pharmaceuticals profitable?

    No. Recursion Pharmaceuticals reported net income of -$644.76M for the fiscal year ended Dec 31, 2025, with a net margin of -863.4%.

    How much free cash flow does RXRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$371.81M minus capital expenditures of $6.47M produced free cash flow of -$378.28M.

    How much debt does Recursion Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $9.56M, short-term debt of $9.09M and cash and equivalents of $743.29M.